Arcellx
Arcellx is a clinical-stage biotechnology company developing engineered CAR T-cell immunotherapies — notably the BCMA-directed anito-cel for multiple myeloma built on its proprietary D-Domain platform — serving relapsed/refractory hematologic cancer patients in partnership with Gilead/Kite.
- Company typePublic
- Founded2014
- HeadquartersRedwood City, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Arcellx does
Arcellx is a clinical-stage biotechnology company that develops engineered cell-based immunotherapies for the treatment of cancer and other serious diseases. The company's lead program is anito-cel (anitocabtagene autoleucel), a BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma built on Arcellx's proprietary D-Domain technology platform, which is also intended to support next-generation in vivo cell therapy applications. Anito-cel had reported Phase 2 iMMagine-1 data showing a 96% overall response rate and a 74% complete response/stringent complete response rate, and held FDA Fast Track, Orphan Drug, and RMAT designations, with a BLA accepted for review and a PDUFA action date of December 23, 2026. Arcellx operated under a co-development and commercialization agreement with Gilead Sciences' Kite Pharma subsidiary, signed in December 2022 and expanded in November 2023 with an $85M upfront payment and a $200M equity investment that extended its runway into 2027. Pre-commercial, Arcellx generated only minimal partnership revenue (approximately $1.65M in Q4 2025; analyst consensus of roughly $12.5M for full-year 2025), and the company was acquired by Gilead Sciences for approximately $7.8 billion in April 2026, with Gilead subsequently eliminating about 87% of the inherited workforce.
Arcellx firmographics
Firmographics- Name
- Arcellx
- Legal name
- Arcellx, Inc.
- Website
- https://arcellx.com
- Company type
- Public
- Founded year
- 2014
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- Arcellx is a clinical-stage biotechnology company developing engineered CAR T-cell immunotherapies — notably the BCMA-directed anito-cel for multiple myeloma built on its proprietary D-Domain platform — serving relapsed/refractory hematologic cancer patients in partnership with Gilead/Kite.
- Ownership category
- akta.pro rank
Arcellx industry classification
Industry- Product category
- Cell Therapy / Oncology Biologics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
- akta.pro secondary industries
- Cell Therapy Developers (Autologous) (HLAAABAA), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
Keywords
Where Arcellx is headquartered
LocationHeadquarters
- HQ city
- Redwood City
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Arcellx business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Partnership/Collaboration Revenue: Co-development partnership with Gilead/Kite involving shared costs, profits, and investments. Received $85 million upfront payment and $200 million equity investment from Kite in 2023 expansion.
- Equity Investment: $200 million equity investment from Kite extending operational runway into 2027
Go-to-market motion2 records
Distribution channels1 record
Marketing channels1 record
Arcellx product offering
Product offeringCore offering
Arcellx is a clinical-stage biotechnology company developing engineered cell-based immunotherapies for cancer and other serious diseases, centered on anito-cel (anitocabtagene autoleucel), a BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma built on its proprietary D-Domain technology platform. The company operated through a strategic co-development and commercialization partnership with Gilead Sciences' Kite Pharma subsidiary for global manufacturing, regulatory, and commercial reach.
Product overview
Arcellx is a clinical-stage biotechnology company developing cell therapies for cancer and incurable diseases. The company's portfolio centers on anito-cel (anitocabtagene autoleucel), a BCMA-directed CAR T-cell therapy for multiple myeloma built on its proprietary D-Domain technology platform. The ARC SparX platform supports next-generation cell therapy development. The company operated through a partnership with Gilead's Kite subsidiary until Gilead completed its $7.8 billion acquisition in April 2026, gaining full ownership of the anito-cel therapy and eliminating profit-sharing arrangements.
Differentiator
Problem solved
Functional benefit
Brands
- CART-ddBCMA: A CAR T-cell therapy for multiple myeloma and lymphoma, co-developed with Gilead's Kite Pharma subsidiary. Also referred to as anito-cel (anitocabtagene autoleucel).
Products and services
- anito-cel (anitocabtagene autoleucel) Investigational BCMA-directed autologous CAR T-cell therapy for the treatment of relapsed or refractory multiple myeloma, developed using Arcellx's proprietary D-Domain technology. Received FDA Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy (RMAT) designations; BLA accepted with PDUFA action date of December 23, 2026.
- CART-ddBCMA CAR T-cell therapy targeting BCMA for lymphoma and multiple myeloma, advanced through the Gilead/Kite partnership. Referenced as the development program name for anito-cel under the Kite co-development arrangement.
- D-Domain Technology Platform Proprietary D-Domain binder platform that underpins Arcellx's CAR-T pipeline, including anito-cel. The platform enables a novel binder architecture that Gilead identified as a potential foundation for next-generation in vivo cell therapy applications.
Quantifiable outcome
- 96% overall response rate (ORR) in Phase 2 iMMagine-1 trial
- +1 more outcomes
Companies that use Arcellx
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
Arcellx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Arcellx partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Gilead Sciences / Kite PharmacoreGilead acquired remaining shares of Arcellx for $7.8 billion at $115 per share plus $5 CVR. Gilead previously owned ~11.5% of Arcellx. Deal gives Gilead full control of anito-cel and eliminates profit-sharing, milestone, and royalty obligations. Expected to close Q2 2026.
- Gilead Sciences / Kite PharmacoreExpanded collaboration in blood cancer treatments including advancing CART-ddBCMA therapy for lymphoma and multiple myeloma. Deal involves $85 million upfront payment and $200 million equity investment from Kite, extending Arcellx's operational runway into 2027.
- Gilead Sciences / Kite PharmacoreStrategic collaboration to develop and commercialize Arcellx's late-stage product CART-ddBCMA for multiple myeloma. Partnership involves co-development, shared costs, profits, and investments with goal of accelerating patient access to therapy.
Scale indicators7 records
Recent moves8 records
Expansion highlights5 records
Arcellx competitors and assessment
Company assessmentDirect peers
- Legend Biotech: Co-developer with Johnson & Johnson of Carvykti (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy approved for relapsed/refractory multiple myeloma. Direct competitor to Arcellx's anito-cel in the same indication and same target class.
- Bristol Myers Squibb (Celgene): Markets Abecma (idecabtagene vicleucel), the first FDA-approved BCMA-directed CAR-T therapy for multiple myeloma. Anito-cel will compete head-to-head with Abecma in relapsed/refractory MM.
- 2seventy bio: Spun out from bluebird bio, originally co-developed Abecma with BMS and continues to work on next-generation cell therapies for hematologic malignancies, directly overlapping with Arcellx's multiple myeloma focus.
Broad incumbents
- Gilead Sciences / Kite Pharma: Acquirer of Arcellx and operator of the world's largest dedicated in-house cell therapy manufacturing network; commercializes Yescarta and Tecartus CAR-T therapies. Comparable as the incumbent cell therapy player that validated Arcellx's technology.
Others
- Novartis: Pioneer of autologous CAR-T therapy with Kymriah (tisagenlecleucel); operates a global cell and gene therapy manufacturing footprint and competes broadly in hematologic oncology cell therapy.
Emerging players
- Allogene Therapeutics: Clinical-stage company developing allogeneic ('off-the-shelf') CAR-T therapies, including BCMA-directed candidates. Comparable to Arcellx in cell therapy modality but differentiated by an allogeneic versus autologous manufacturing approach.
- CRISPR Therapeutics: Clinical-stage gene editing company developing gene-edited allogeneic CAR-T therapies, including BCMA-directed candidates. Comparable as a next-generation cell therapy peer pursuing hematologic malignancies.
- Caribou Biosciences: Clinical-stage allogeneic CAR-T developer using CRISPR-based genome editing; relevant peer for cell therapy modality and hematology/oncology pipeline overlap.
- Adaptimmune: Develops engineered T-cell therapies including TCR-T therapies for solid and hematologic cancers; comparable as a cell therapy developer in oncology with similar regulatory and manufacturing dynamics.
- Iovance Biotherapeutics: Focused on tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors with an FDA-approved product; comparable as a commercial-stage cell therapy peer with similar manufacturing complexity and oncology focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Arcellx social profiles
Digital presenceArcellx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Arcellx leadership team
Management profileNumber of profiles
Profiles1 record
Arcellx funding detail
Funding detailFunding overview
Funding rounds7 records
Investors25 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Arcellx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Arcellx
What does Arcellx do?
Arcellx is a clinical-stage biotechnology company developing engineered cell-based immunotherapies for cancer and other serious diseases, centered on anito-cel (anitocabtagene autoleucel), a BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma built on its proprietary D-Domain technology platform. The company operated through a strategic co-development and commercialization partnership with Gilead Sciences' Kite Pharma subsidiary for global manufacturing, regulatory, and commercial reach.
Is Arcellx a public or private company?
Arcellx is a public company. It is classified as corporate owned and is currently acquired.
When was Arcellx founded?
Arcellx was founded in 2014. It employs 101 to 250 people.
Where is Arcellx based?
Arcellx is headquartered in Redwood City, United States, in the North America region.
How does Arcellx make money?
Two revenue lines are on record. Partnership/Collaboration Revenue is the primary driver. The others are equity Investment.
Who are Arcellx's main competitors?
Direct peers on record are Legend Biotech, Bristol Myers Squibb (Celgene) and 2seventy bio. Gilead Sciences / Kite Pharma is listed as a broad incumbent. Novartis is listed as an others. Emerging players are Allogene Therapeutics, CRISPR Therapeutics, Caribou Biosciences, Adaptimmune and Iovance Biotherapeutics.
Does Arcellx have an API?
No public API is recorded for Arcellx.
What industry is Arcellx in?
Arcellx's product category is Cell Therapy / Oncology Biologics. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAA, Cell Therapy Developers (Autologous). Its NAICS code is 325414 and its SIC code is 2834.